Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Lung Neoplasms 49Breast Neoplasms 24Head and Neck Neoplasms 21Adenocarcinoma of Lung 18Brain Neoplasms 15Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 9Esophageal Neoplasms 9Colorectal Neoplasms 9Rectal Neoplasms 7Prostatic Neoplasms 7Neoplasm Metastasis 7NSCLC 7Gliosarcoma 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Respiratory Tract Diseases 3Kidney Neoplasms 3

Interventions

Adrenalectomy 3Radiosurgery 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1iodophenyl metomidate 1camrelizumab 1apatinib 1X-Rays 1Radiofrequency Ablation 1Observation 1Nephrectomy 1N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride 1Mitotane 1Gefitinib 1Floxuridine 1Erlotinib Hydrochloride 1Dexamethasone 1Cystectomy 1Cryosurgery 1Adosterol 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adrenal Gland Neoplasms × Gefitinib × Clear all
NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
16 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡